Let's look objectively at both the science and the management, both of which are essential to the success of any company and only can blind assertions and blind criticisms.
I happen to enjoy watching "The Profit" TV show from time to time. One thing that always stands out to me is how very good products and visions can fail because of the personality of the person in charge.
Yes, the science seems to be advancing (in spite of losing the 2 main scientists the company's recent IP is founded on: T. Ichim and C. Ichim (for those who think she's still there because the company hasn't said otherwise - a point in itself, why would the person with the research of NR2F6, suddenly disappear from all appearances at conferences and any mention in any PR when she was previously the main figure?).
HemaXellerate finally got approval - yahooo! Back in December of 2015!! Since December 2015, what is the share increase in RGBP as well as going live with RGBPP and how many bonus and other shares have been issued without money being set aside to commence HemaXellerate trials? 9 months out from a green light and we are at a Stop Sign with the engine turned off or idling. The letter from Landers was for human trials to have begun by end of 3rd Qtr - they did not, but he got 10 million shares just for HemaXellerate approval before he came on board - huh?
NR2F6 seems to be going forward, but at least the PR states it is a long way away, so it must be a LONG, LONG way away.
dCellVax response was filed - late, but filed. Let's hope
HemaXellerate IND expansion was to be filed by now, but no word and last word on it was that they were still planning on filing it.
So, yes, I recognize there is progress on a scientific level.
Now let's objectively look at management with superlatives, ok, fine.
HemaXellerate IND was filed in Feb 2013 if I recall correctly (or was it 2011?), its been so long. It was projected to end in human trials before end of 2014. We went months without news until they finally had to admit that all the testing did not meet FDA requirements (during the period we had just heard that they were in discussions with the FDA and hoped to resolve everything quickly).
dCellVax IND was supposed to be filed in June 2014 which also gave us hope. Just recently was a response to dCellVax issues filed with the FDA.
Wei Ping Min was the main outside scientist helping BMSN with HemaXellerate along with the likes of people like David Sully and a whole entourage of scientists being paid for a monthly conference call to the toon of tens of thousands of dollars a year. Haven't heard of any concrete contributions from anyone other than the original science of Wei Ping Min.
Since then, we've had 3 people that were hired and paid to raise funds and are now with an "Exclusive" agreement with yet an additional party whose specialty is $1-$4 million dollar contracts (hardly the billions people speak of here). And because Koos/Landers signed over exclusive licensing, the company has limited itself.
We've added on scores of outside scientific "consultants" while losing the two main scientists who were hired, signed over their IP and were the ones moving the science and company forward throughout all of 2015. WHY? Not a good sign.
Before than, Koos fired Christopher Mizer, who was the main person giving the scientific presentations for BMSN.
Over the years, one thing has remained consistent, the only money revolving in and out of the company comes from loans from Koos that he can turn into shares at high discounts and sell later and in last couple of years to Friends and Family share plan.
The management style and history of Koos and the companies he has run is sadly consistent. He does not retain the few highly qualified people he ever surrounds himself with and everything he does, benefits himself to an extraordinary degree.
An objective review of Koos and the Company reveals a slow progress of the science with a lot of mistakes that have delayed its potential in a highly competitive industry. But somehow Koos always has money to loan to the company in return for shares (Do you ever wonder where he gets it, since the company has so few employees and he is supposedly running everything - from where does he get his own money?)
Koos fires the people who actually have benefitted the company while holding and paying out to people who do not seemingly do their jobs, like the list of in house paid fund raisers.
The relationships we have with NCATS, Eli Lilly, Dr. Kesari where established by those no longer with the company, cutting off the positive, in house relationships - not a good sign.
So in my objective view having been here for over 3 years and reading the filing and the non filings and observing the management of the company, both for science and personnel, we cannot be confident anymore that the science will save the company and us. The science may very well succeed only to benefit the insiders who may have issued the 500 million shares for one symbol and the 700-800 million shares for the other symbol directed associated with Regen.
We started with 20 million shares in the RGBP float and .20-.40 range. We are now over 270 million shares in the .12 -.20 range which means the company's science has increased the value of the company from $15M range to $40M range while the common outsider shareholder has lost money on the investment. Do the math, if we go to 1.3B shares outstanding in order to raise some funds, the value of .15/share brings the company from $40M value to $200M without us recuperating our losses, but hey, Koos and Company will do just fine.
So we must recognize, they can win and we can lose even if the science is successful.
You may say that the science is worth $600M just for one or the other pipeline product, and that may be true, but it all comes down to management at that point and how they construct the contract/licensing, getting bought out....
